Literature DB >> 15454094

Histochemical evaluation for the biological effect of menatetrenone on metaphyseal trabeculae of ovariectomized rats.

Y Asawa1, N Amizuka, K Hara, M Kobayashi, M Aita, M Li, S Kenmotsu, K Oda, Y Akiyama, H Ozawa.   

Abstract

To evaluate the biological effects of vitamin K2 (menatetrenone, MK-4) on ovariectomy (OVX)-induced bone loss, we have examined histological alterations of femoral metaphyses of sham-operated (sham group), ovariectomized (OVX group), and MK-4 dietary-supplemented OVX (MK-4 group; 50 mg/kg per day) female Fischer rats 1, 2, 5, and 8 weeks after OVX. In the first week, rats of the OVX and MK-4 groups showed discontinuous trabeculae compared with sham-operated rats. At 2 weeks after OVX, the OVX rats revealed many large tartrate resistant acid phosphatase (TRAP)-positive osteoclasts, while osteoclasts in the MK-4-treated rats were similar in size to those of the sham group. At 5 weeks, the OVX and MK-4 groups revealed fragmented trabeculae in femoral metaphyses. The cartilage matrix was partially exposed due to stimulated bone resorption in the OVX group, but not in the MK-4 group. After 8 weeks, the OVX rats had little metaphyseal trabeculae, whereas the MK-4-treated rats had maintained short trabeculae. Despite the presence of intense alkaline phosphatase-positive osteoblasts on trabeculae in the MK-4 group, TRAP-positive osteoclasts were flattened without developing ruffled borders. Therefore, MK-4 appeared to lessen the increase in osteoclastic bone resorption induced by OVX, as well as to maintain the accelerated osteoblastic activity. It is of importance to identify the target cells for MK-4 in bone. Autoradiography localized [3H]-labeled MK-4 mainly in osteoblasts and adjacent bone matrices, but not in osteoclasts, indicating that MK-4 targets osteoblasts. Thus, MK-4 appears to target osteoblasts, consequently inhibiting bone loss induced by ovariectomy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454094     DOI: 10.1016/j.bone.2004.06.007

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

1.  Vitamin K catabolite inhibition of ovariectomy-induced bone loss: structure-activity relationship considerations.

Authors:  Robin J Soper; Cenk Oguz; Roger Emery; Andrew A Pitsillides; Stephen J Hodges
Journal:  Mol Nutr Food Res       Date:  2014-07-14       Impact factor: 5.914

2.  Effect of vitamin K2 and growth hormone on the long bones in hypophysectomized young rats: a bone histomorphometry study.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato; James K Yeh
Journal:  J Bone Miner Metab       Date:  2007-01-01       Impact factor: 2.626

3.  Effects of vitamin K2 on the development of osteopenia in rats as the models of osteoporosis.

Authors:  Jun Iwamoto; Tsuyoshi Takeda; Yoshihiro Sato
Journal:  Yonsei Med J       Date:  2006-04-30       Impact factor: 2.759

Review 4.  Vitamin K and Bone Metabolism: A Review of the Latest Evidence in Preclinical Studies.

Authors:  Solmaz Akbari; Amir Alireza Rasouli-Ghahroudi
Journal:  Biomed Res Int       Date:  2018-06-27       Impact factor: 3.411

Review 5.  Positive and negative regulators of osteoclast apoptosis.

Authors:  Niroshani Surangika Soysa; Neil Alles
Journal:  Bone Rep       Date:  2019-10-21

6.  Effect of Vitamin K2 Alone or in Combination on Various Bone Turnover Markers Amongst Postmenopausal Females.

Authors:  Lamia AlHajri; Amna Ayoub; Hessa Ahmed; Marwa AlMulla
Journal:  J Bone Metab       Date:  2021-02-28

7.  Effects of multi-deficiencies-diet on bone parameters of peripheral bone in ovariectomized mature rat.

Authors:  Thaqif El Khassawna; Wolfgang Böcker; Parameswari Govindarajan; Nathalie Schliefke; Britta Hürter; Marian Kampschulte; Gudrun Schlewitz; Volker Alt; Katrin Susanne Lips; Miriam Faulenbach; Henriette Möllmann; Daniel Zahner; Lutz Dürselen; Anita Ignatius; Natali Bauer; Sabine Wenisch; Alexander Claus Langheinrich; Reinhard Schnettler; Christian Heiss
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.